Shanghai Junshi Biosciences Enters Licensing Agreement for Dual-Targeted Fusion Proteins
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a China-based biopharmaceutical company, has announced...
Cancer
EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...
EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment
Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...
Impact Therapeutics Secures $34.5 Million in Series D++ Financing for Senaparib Commercialization
China-based biopharmaceutical company Impact Therapeutics has reportedly secured RMB 250 million (USD 34.5 million) in...
Sanofi’s Sarclisa Receives CHMP Recommendation for Newly Diagnosed Multiple Myeloma
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that the Committee for Medicinal Products for...
Merck Secures Exclusive Rights to LaNova’s PD-1/VEGF Bispecific Antibody LM-299
US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced a significant...
Sino Biopharmaceutical’s TQB3002 Receives FDA Clearance for Phase I Study
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based pharmaceutical company, has announced that it has...
Mabwell Bioscience Receives NMPA Approval for 9MW2821 Clinical Trials
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...
Jiangxi Jemincare’s JMX-2002 Liposome Injection Gets NMPA Clinical Clearance
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced that it has received clinical clearance...
Lion TCR Gains NMPA Approval for mRNA TCR-T Therapy GZL-016 in HCC
Singapore-based clinical-stage biotechnology company Lion TCR, supported by Chinese investors, has secured tacit clinical approval...
ImmuneOnco Initiates Phase II Study for IMM27M in ER+ Advanced Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a leading biopharmaceutical company specializing in immuno-oncology, has...
Novartis’ Pluvicto Accepted for Review by China’s NMPA for Prostate Cancer Treatment
The Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has accepted...
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...
Canhelp Genomics Partners with Mirxes to Expand Tumor Origin Testing in Southeast Asia
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership...
ETERN Therapeutics’ ETS-006 Receives FDA Orphan Drug Designation for Pleural Mesothelioma
ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced that it has received...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...
Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024
Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...
Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...